AMGEN INC — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Amgen reported Q2 2026 total revenues of $10.1B (+10% YoY), with product sales of $9.537B (+9%). Six key growth drivers grew 26% YoY and generated ~70% of product sales. GAAP EPS increased 65% to $4.37; non-GAAP EPS rose 4% to $6.29. The company raised dividend 6% to $2.52/share and generated $3.5B free cash flow (vs. $1.9B prior year). Full-year 2026 guidance: revenues $38.2–$39.4B; GAAP EPS $15.80–$17.08; non-GAAP EPS $22.30–$23.50.
Why this rating
Strong organic growth with modest margin pressure; core guidance reaffirmed. Material for a $150B company but not transformational—routine quarterly result at scale.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.